ALK

(redirected from Anaplastic Lymphoma Kinase)
Also found in: Medical.
AcronymDefinition
ALKSrilankan Airlines (ICAO code)
ALKAlkohol (German: alcohol)
ALKAlkaline
ALKAnaplastic Lymphoma Kinase
ALKAlkylation
ALKActivin Receptor-Like Kinase
ALKAlaska Air Group, Inc. (stock symbol)
ALKAutomated Limellar Keratoplasty (Surgical Procedure)
ALKAutomatisierte Liegenschaftskarte
ALKAnti-Lift Kit (Subaru suspension system)
ALKAllergologisk Laboratorium København (Allergological Laboratory of Copenhagen)
ALKAssociation Languedocienne de Kyudo (French; Japanese archery association)
References in periodicals archive ?
12) Anaplastic lymphoma kinase is a receptor tyrosine kinase (RTK), which is inactive in its native form.
Abbreviations IMT: Inflammatory myofibroblastic tumor CBI: Continuous bladder irrigation ALK: Anaplastic lymphoma kinase.
Keywords: Anaplastic large cell lymphoma (ALCL), Anaplastic lymphoma kinase (ALK), Non-Hodgkin lymphoma.
4] The human ALK gene spans a region of about 728 kb on chromosome 2p23 and encodes anaplastic lymphoma kinase, a tyrosine kinase receptor and member of the insulin growth factor receptor superfamily which is normally expressed in the central nervous system.
Further, a wave of new anaplastic lymphoma kinase inhibitors and a second-generation heat shock protein 90 inhibitor are making headway as potential targeted NSCLC treatments.
The emerging pathogenic and therapeutic importance of anaplastic lymphoma kinase.
Crizotinib is an oral drug from a new class of cancer medicines that inhibits a gene called anaplastic lymphoma kinase (ALK).
Two pathologic subtypes of systemic ALCL are recognized according to the presence of a translocation involving the Anaplastic Lymphoma Kinase gene known as ALK.
Mutations of a gene called anaplastic lymphoma kinase (ALK) are behind most incidences of hereditary neuroblastoma, a rare and deadly childhood cancer, as well as high-risk noninherited forms of the disease, a new study suggests.
US-based cancer therapeutics developer Xcovery has initiated its Phase 2 clinical trial of ensartinib (X-396), the company's lead anaplastic lymphoma kinase drug candidate, in patients with advanced malignant melanoma harboring alterations in ALK, including ALKATI, the company said.
According to a Pharma Times article published on Tuesday, the move will permit physicians to prescribe the drug in treatment-naive patients with metastatic NSCLC whose tumours are anaplastic lymphoma kinase (ALK)-positive.